


Novel nuclear medicine approach shows promise for treating wide array of cancerous tumors

June 25 2018



²²⁵Ac-proteus-DOTA hapten can be targeted in vivo to GPA33-expressing human colorectal cancer xenografts using anti-GPA33-DOTA-PRIT, with minimal radioactive uptake in critical radiosensitive tissues such as blood and kidney. In addition, indium-111 can be used in place of ²²⁵Ac as a convenient imaging surrogate (biomarker) of ²²⁵Ac in vivo biodistribution and dosimetry. Credit: SM Cheal et al., Memorial Sloan Kettering Cancer Center, New York, NY.

A novel nuclear medicine approach is showing great promise for precision treatment of solid tumors in many types of cancer—including lung, breast, pancreas and ovarian in adults and glioma, neuroblastoma and sarcoma in children. The research was presented today at the SNMMI 2018 Annual Meeting, June 23-26 in Philadelphia.

In 2017, researchers from Memorial Sloan Kettering Cancer Center developed a novel approach to pretargeted radioimmunotherapy (DOTA-PRIT) that demonstrated preclinically, complete responses, including cures, in several solid [tumor](#) types using the beta-emitting lutetium-177 (^{177}Lu)-DOTA-hapten. In the research presented today, the researchers expanded the DOTA-PRIT approach to actinium-225 (^{225}Ac), an alpha-emitting isotope.

"Targeted alpha radiotherapy has shown considerable promise for patients, especially for those with advanced castration-resistance prostate [cancer](#)," said Steven M Larson, MD and Sarah M. Cheal, Ph.D., of the Program in Molecular Pharmacology and Department of Radiology at Memorial Sloan Kettering Cancer Center in New York. "By combining DOTA-PRIT with ^{225}Ac -proteus-DOTA hapten, we can potentially target a wide array of cancer types for which we have validated DOTA-PRIT bispecific antibodies (GD2-expressing, HER2-expressing, and GPA33-expressing cancers)."

DOTA-PRIT has a major advantage over other forms of radioimmunotherapy because of its very high ability to deliver radiation to tumors while sparing normal tissues, such as kidney and bone marrow. Larson and Cheal explained, "Creating a targeting alpha radiohapten greatly expands the potential for killing small nests of cells and even single cancer cells, which is likely to be important early in the course of metastatic spread."

Researchers synthesized proteus-DOTA, radiolabeled it with ^{225}Ac , and

conducted in vitro and in vivo studies of a mouse model with colorectal cancer to determine if pretargeting the tumor with ^{225}Ac -proteus-DOTA hapten was feasible. A toxicity study was performed in normal tumor-free athymic nude mice with varying dose levels of ^{225}Ac -proteus-DOTA given as a single intravenous injection. Mice were monitored daily for 145 days post-injection and weighed up to twice weekly for evidence of treatment-induced toxicity.

Researchers found that their new approach, ^{225}Ac -proteus-DOTA, mimics the behavior of the previously developed approach, ^{177}Lu -DOTA-hapten, with high tumor uptake, minimal accumulation in normal tissue, good whole-body clearance, no acute toxicity and no chronic radiation damage (see figure below). In addition, the new approach offers greater versatility of treatment for a wide variety of solid tumors and clinical situations.

Larson and Cheal pointed out, "When solid tumors spread beyond surgical control, they are the deadliest tumors for cancer patients. Using the DOTA-PRIT approach, we hope to greatly expand the potential of delivering precision radioimmunotherapy to human [solid tumors](#)."

More information: Scientific Paper 123: "Pretargeted radioimmunotherapy with ^{225}Ac -proteus-DOTA hapten," Sarah M. Cheal and Miteshkumar V. Patel, Program in Molecular Pharmacology; Michael R. McDevitt and Steven M. Larson, Radiology; Guangbin Yang and Ouathek Ouerfelli, Organic Synthesis Core Facility; NagaVaraKishore Pillarsetty, Radiochemistry and Imaging Sciences Service; Hong Xu, Hong-fen Guo, and Nai-Kong Cheung, Pediatrics; and Edward K. Fung, Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY. SNMMI 2018 Annual Meeting, June 23-26, 2018, Philadelphia. jnm.snmjournals.org/content/59...4c-a022-94a3d42ab48c

Provided by Society of Nuclear Medicine and Molecular Imaging

Citation: Novel nuclear medicine approach shows promise for treating wide array of cancerous tumors (2018, June 25) retrieved 13 July 2024 from

<https://medicalxpress.com/news/2018-06-nuclear-medicine-approach-wide-array.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.